Objective: The aim of this study was to examine the association between fracture and pelvic organ prolapse (POP) in postmenopausal women enrolled in the Women's Health Initiative Estrogen Plus Progestin trial.
P elvic organ prolapse (POP) is a recognized contributor to morbidity in an aging female population 1, 2 and to the overall healthcare cost in the community. More than 300,000 surgical procedures are reportedly performed annu-ally for POP in the United States, with an incurred cost in excess of $1 billion. 3, 4 The prevalence of POP attests to the magnitude of its potential healthcare burden. As many as 41% of postmenopausal (PM) women enrolled in the Women's Health Initiative Estrogen Plus Progestin (WHI-EP) trial demonstrated some degree of POP. 2 Both qualitative and quantitative deficiencies in pelvic collagen are believed to exist in women with POP. 5<14 Conversely, a predisposition to POP is identified in women with generalized connective tissue disorders. 15 The role of skeletal collagen in conferring architectural tissue strength is underscored by an increased incidence of fractures in collagen disorders like Marfan and Ehlers-Danlos syndromes. 16<18 Limited data are suggestive of global collagen deficiency in women with evidence of POP. 14,19<21 Pursuing a hypothesis that PM women with evidence of POP may be at an enhanced lifetime risk for skeletal fragility, we previously identified an association between moderate to severe POP and compromised skeletal integrity in the PM population. 22 Analyses of baseline data from the WHI-EP trial revealed a higher prevalence of low bone mineral density (BMD) and an enhanced likelihood for fractures (after age 55 y) in PM women identified with moderate to severe POP compared with those with absent to mild POP, 22 thus expanding the spectrum of health concerns associated with POP.
Extending our earlier observations, we herein demonstrate that PM women with moderate to severe POP are significantly more likely to experience incident fractures compared with those with absent to mild POP. The current study was undertaken using the longitudinal data on PM women recruited in the WHI-EP Trial, details of which have previously been published. 23 
METHODS

Study population
In the WHI-EP randomized controlled trial, 16,620 PM women aged from 50 to 79 years with an intact uterus at baseline were recruited at 40 US clinical centers between September 1993 and July 2002; 12 were subsequently excluded because of a change in the hysterectomy status. The participants (16, 608) were randomly assigned to receive conjugated equine estrogens, 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n = 8,506) versus placebo (n = 8,102).
POP was evaluated at baseline through a standardized pelvic examination 2 and was documented as either absent or present; if present, it was categorized into distinct anatomical types, that is, cystocele, rectocele, or uterine prolapse. The severity of POP was graded with reference to the introitus. Three grades of increasing descent of pelvic organs were described: mild (descent of the most dependent part of pelvic organs into the vagina but not reaching the introitus), moderate (descent down to the level of the introitus), and severe (descent beyond the introitus). All assessments were performed with the participant in a supine position and performing the Valsalva maneuver. 2 Moderate to severe POP was stated as the exposure variable (independent) for the assessment of a relationship with an incident fracture by the bone site (dependent).
Independent variables of interest included age, race/ethnicity (white, black, Asian, Hispanic, other), gynecologic history including age at menarche (categorized as G9, 9-13, and Q14 y), history of regular periods in premenopausal years (yes/no), age at menopause (in years), parity, history of previous use of hormone therapy (HT; never, G5 y, 5-9 y, Q10 y), history of use of oral contraceptive (ever/never), medical history including any history of thyroid disorders (any type, yes/no), asthma (yes/no), emphysema (yes/no), social history including a history of smoking 100 cigarettes or more ever (yes/no), physical activity (energy expenditure in metabolic equivalents per week), history of falls in past 12 months (yes/no), family history of bone fractures (broken bone in mother or father, yes/no), and current use of calcium and/or vitamin D supplements. Anthropometric measures included body mass index (BMI) and waist-to-hip ratio both as continuous variables. Parity was available as an ordinal variable (j1 to 9; j1, never having been pregnant; 0, never had a term pregnancy). Parity was recoded as Bnulliparous[ if there was no history of a previous live birth. Menarche at 14 years or older was coded as Blate menarche,[ and menopause at an age younger than 45 years was defined as Bearly menopause.[ HT was dichotomized as never/ever. The annual household in-come, reflecting the socioeconomic status (SES), was dichotomized at $50,000 as previously described. 24 
Outcome measures and follow-up
Fracture outcomes were ascertained using a semiannual questionnaire and included hip, wrist/lower arm, clinical vertebral, and total fractures. 24 Reported events were verified by local and central adjudication involving a review of radiological reports. For the analysis presented, the primary outcome measures were Bany fracture[ and the site of fracture (hip, spine, and lower arm). The WHI-EP trial was terminated after an average of 5.6 years; in the study presented, the participants were followed over 7.41 (2.18) years. The follow-up time was calculated from the date of study entry to the date of fracture or date of last examination, whichever came first. Those with missing follow-up data (n = 53) and POP status (n = 1) and known osteoporosis at baseline (n = 794) were excluded from the present analyses; 15,760 PM women constituted the study sample to explore the hypothesis that moderate to severe POP is a risk factor for fracture in PM women ( Fig. 1 ).
Statistical analysis
Demographic and clinical characteristics were compared between those with moderate to severe POP and those with absent to mild POP using two sample t tests and W 2 tests for continuous and categorical variables, respectively.
Cox proportional hazards models were constructed to evaluate the effect of POP on fracture. The proportional hazards assumption was tested using Schoenfeld residuals and by comparing the plot of the log (Ylog [survival]) with the log of survival time; if the graph resulted in parallel lines, the predictor variable was considered Bproportional.[ 25 Adjustment variables included those independent variables that were previously recognized to be associated with the likelihood for fracture at an age greater than 55 years in our previous analyses using the baseline data for the cohort 22 and the included age, race/ethnicity, early menopause, parity (yes/no), hormone use (ever/never), regular periods in premenopausal years (yes/ no), BMI (in kilograms per square meters), history of thyroid disorders, history of asthma, history of ever smoking 100 cigarettes or more, history of falls, family history of bone fractures (broken bones in mother or father), SES, metabolic equivalents, current use of calcium and vitamin D supplementation, and intervention arm (HT vs placebo). The interaction product terms were created between POP subtypes and the intervention arm of the clinical trial (HT or placebo), along with the main effect terms in the fully adjusted models.
Given the known propensity for repeat fracture in those with a history of bone fracture, 26 sensitivity analyses were performed after excluding PM women who had previously had a fracture in their lifetime (history of fracture, ever) to determine the association between moderate to severe POP with the risk of a first fracture occurring during the period of observation. Continuous data are presented as mean T SD, whereas categorical data are shown as percentages (n). The magnitude of risk is presented as hazard ratio (HR) and 95% CI. All statistical tests used two-tailed t tests with an > of 0.05 and Stata SE 10.1 for Windows (StataCorp, College Station, TX). Approval from the WHI Publication Committee was obtained before accessing the study database.
RESULTS
Moderate to severe POP (all types) was identified in 1,192 participants (7.56%). Cystocele was the most common anatomic variant (5.32%), followed by rectocele (2.72%), whereas uterine prolapse was noted in 1.20%; additional smaller numbers presented with combinations of the various anatomical (cystocele, rectocele, or uterine) variants of moderate to severe POP. Of the documented incident fractures (n = 2,156), the most common site was the lower arm (28.51%; n = 615) followed by the hip (9.50%; n = 205). Of the hip fractures, most of the first fractures sustained were during the period of observation (81.95%; n = 168).
As shown in Table 1 , compared with women with absent to mild POP, those with moderate to severe POP were older (P G 0.001), were significantly less likely to be black and nulliparous (P G 0.001), and were less likely to smoke (P G 0.001), to report early menopause (P = 0.007), or to acknowledge a previous use of oral contraceptive (P = 0.040) or HT (P G 0.001); those with moderate to severe POP were significantly more likely to be Asian (P G 0.001), to report a previous history of fracture (P = 0.003), to have a higher BMI (P G 0.001), and to have a lower SES as reflected by an annual household income less than $50,000 (P = 0.016).
The association between the various anatomic variants of POP and site-specific incident fractures is presented in Table 2 . The adjusted analyses confirmed moderate to severe POP (any anatomic type and moderate to severe rectocele and cystocele) as independent risks for incident hip fractures.
A statistically significant interaction was observed between incident lower arm fracture with moderate to severe POP and with moderate to severe rectocele (P for interaction = 0.046 and 0.022, respectively) with respect to treatment arm. Stratified analyses by trial assigned intervention (HT versus placebo) identified moderate to severe rectocele as an independent risk factor for incident lower arm (Fig. 2) and spine ( Fig. 3 ) fracture in PM women randomized to placebo but not in those receiving HT.
Hazard ratios for site-specific incident fractures were further assessed comparing PM women with moderate to severe POP with those with absent POP (ie, those with mild POP were excluded from the reference group) and confirmed the stability of the observed associations between moderate to severe POP and incident hip fracture (data not shown). Additional sensitivity analyses excluded those with a history of fracture before enrollment in the trial (Table 3 ). Moderate to severe POP was again identified as a risk for site-specific incident fracture in PM women not taking HT; the highest hazard magnitudes were observed in those with moderate to severe rectocele.
Given the retrospective cohort study design, a likelihood that the observed differences in incident fractures between the two cohorts (ie, those with moderate to severe compared with absent to mild POP) could have resulted from a differential in the duration of follow-up was considered. Interestingly, the mean duration of the follow-up was statistically significantly shorter in women with moderate to severe compared with those with absent to mild POP (7.78 T 1.47 vs 7.97 T 1.57 y, P G 0.001). These findings suggest that the actual magnitude of fracture risk relating to moderate to se-vere POP may even be of a greater magnitude than what is observed.
DISCUSSION
In line with our earlier observation, 22 our current analyses corroborate our hypothesis relating moderate to severe POP in PM women with skeletal fragility. Our analyses of the longitudinal data available on women enrolled in the WHI-EP trial identify moderate to severe rectocele as an independent risk for PM hip fracture. The skeletal siteYspecific predilection to fracture, however, is probably a reflection of power-related constraints, as an enhanced risk for lower arm and spine fractures was also observed in PM women with moderate to Models are adjusted for age, BMI, race, asthma, emphysema, thyroid, family history of fracture, regular menses, age at menopause, nulliparity, hormone use, history of falls, income, calcium supplementation, and METS per week and for HT intervention arm. POP, pelvic organ prolapse; AHR, adjusted hazard ratio; HT, hormone therapy; BMI, body mass index; METS, metabolic equivalents. Y, There were no fractures in this group. severe POP who were assigned to the placebo arm of the clinical trial. These latter observations imply the protective effects of menopausal HT on reducing incident fractures in PM women with moderate to severe POP.
We previously described an association between moderate to severe POP and the likelihood of fracture in aging PM women (960 y). 22 Our current and previous observations have been corroborated by Melton et al, 27 who, in a retrospective cohort study of 9,258 women followed for a median of 13.6 years after hysterectomy, described an association between previous surgery for uterine prolapse and fracture risk.
The consistency of the observed relationships between individual anatomical variants of moderate to severe POP with incident fractures by site on adjusted analyses and on sensitivity analyses add credence to our hypothesis that POP be regarded as a focal manifestation of generalized tissue compromise. A site-specific differential in pelvic connective tissue composition and relationship thereof with the skeletal matrix are suggested by our analyses. Qualitative and possibly quantitative distinctions in the pelvic fascia from anatomically distinct compartments are thus implied, albeit remain far from understood. Intraindividual and interindividual variations in pelvic fascia are well appreciated, and this tissue heterogeneity underlies the lack of consensus regarding embryological origins of the pelvic fascia 28 ; histological distinctions in the fascia of the pelvic compartments are similarly poorly understood. Although the underlying mechanisms unifying the consistently observed relationships between the rectocele and bone fracture remain unclear, these observations underscore a need for appropriately designed studies focusing on sitespecific differences in tissue composition within the pelvic compartments.
A role for the loss of ovarian hormones in the pathogenesis of POP remains far from clear. An increased risk for POP is described in association with polymorphism in estrogen receptorY> as well as in estrogen receptorYA, 29, 30 implying a role for estrogen signaling (or lack of effects thereof) in the pathogenesis of POP. The picture is, however, clouded by inconsistencies in the data relating the presence and progression of POP to the use of menopausal HT or selective estrogen receptor modulators. 31<34 Worsening POP was reported in the PM women randomized to the EP arm of the WHI-EP trial. 31 A similar lack of efficacy against POP was observed with the use of the selective estrogen receptor modulators raloxifene and tamoxifen and conjugated equine estrogens by healthy PM women 32 ; after 20 weeks of intervention, progression in POP was observed in 75% of the participants randomized to raloxifene, 60% of those who received tamoxifen, and 22% of those receiving conjugated equine estrogens. 32 Primary damage to the connective tissue of the pelvic floor occurs during pregnancy and childbirth, and a role for the loss of ovarian hormones concomitant with menopause in the pathogenesis of, or progression in, POP thus remains far from clear.
Based on the current evidence, the role for HT in women with POP is limited to the treatment of symptoms relating to vaginal atrophy. Our data suggest beneficial influences of menopausal HT in reducing fracture risk in PM women with moderate to severe POP. Although these findings reiterate the well-recognized protective effects of HT on fracture risk, 24 future studies are needed to help establish a preventive role for postmenopausal HT in mitigating fracture risk in women with moderate to severe POP.
Although we herein hypothesize that compromised tissue collagen may be a mechanism that unifies POP (reflective of a weakened pelvic floor) and skeletal fragility, our data cannot elucidate the underlying pathophysiological mechanisms. The relatively subjective nature of the evaluations and the supine positioning of the participants at the time of POP grading 33, 34 are limitations intrinsic to the study design that may have compromised the sensitivity in detecting lesser grades of POP. We attempted to redress this latter concern by targeting the obvious descent of pelvic organs as our variable of interest, 22 thus confining our definitions to the more severe degrees of POP. In the subset of women who underwent BMD assessment at baseline, our previous analyses 22 identified significantly lower total body BMD in those with moderate to severe POP. Although the paucity of incident fracture events in the limited cohort who did undergo BMD testing (BMD was evaluated in a subset only [n = 1,024]; 46 of 958 women with moderate to severe POP and 634 of 10,101 women with absent to mild POP underwent BMD evaluation) limits us from commenting on the contributions of deteriorating BMD to fracture risk, we attempted to address this deficiency by excluding those with a known history of osteoporosis and those with a previous history of fracture. Although the direction and the magnitude of HRs for the observed associations between individual anatomical variants of moderate to severe POP and fracture site were maintained in the sensitivity analyses, the resulting model instability (widening of CIs) and the loss of statistical significance to some of the associations probably reflect power constraints.
CONCLUSIONS
Our analyses of longitudinal data for the WHI-EP cohort identify moderate to severe POP, a prevalent gynecological entity, as an independent risk factor for incident fracture in PM women. We reaffirm the previously observed relationships 22 between moderate to severe POP, in general, and moderate to severe rectocele, in particular, and skeletal fragility. Considering the prevalence of POP in PM women (almost 8% of PM women enrolled in the WHI-EP trial demonstrated moderate to severe POP) and the observed association with incident hip fractures (which have the highest morbidity and mortality), our findings hold public health implications. 35 Although our analyses suggest that HT was protective against incident fracture in PM women with moderate to severe POP, these findings must be interpreted with caution given the retrospective nature of our analyses, our inability to comment on the occurrence of Bnoninformative[ events given the limitations intrinsic to working with an existing dataset, and the wide CIs that are probably reflective of power constraints. It should be noted that the comparable efficacy data for commonly used antiresorptive treatments other than HT (eg, bisphosphonates, selective estrogen receptor modulators, calcitonin, or parathyroid hormone) have not been specifically substantiated in this population of PM women identified at risk for fracture. Our findings suggest that the considerations on the choice of fracture prevention therapy in PM women should incorporate the status of pelvic organ descent.
